WO1998051318A1 - Pharmaceutical composition and diagnostic kit directed to a heterologeneous pathogenic organism in a host - Google Patents

Pharmaceutical composition and diagnostic kit directed to a heterologeneous pathogenic organism in a host Download PDF

Info

Publication number
WO1998051318A1
WO1998051318A1 PCT/EP1998/002871 EP9802871W WO9851318A1 WO 1998051318 A1 WO1998051318 A1 WO 1998051318A1 EP 9802871 W EP9802871 W EP 9802871W WO 9851318 A1 WO9851318 A1 WO 9851318A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
self
pathogenic organism
heterologeneous
infections
Prior art date
Application number
PCT/EP1998/002871
Other languages
French (fr)
Inventor
Jens Pohl
Rolf Bechtold
Michael Paulista
Othmar Dill
Original Assignee
Biopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopharm Gmbh filed Critical Biopharm Gmbh
Priority to EP98930692A priority Critical patent/EP0983077A1/en
Priority to CA002289610A priority patent/CA2289610A1/en
Priority to AU81043/98A priority patent/AU8104398A/en
Publication of WO1998051318A1 publication Critical patent/WO1998051318A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a pharmaceutical composition comprising a self- replicating agent directed to a heterologeneous pathogenic organism in a host, and to a process for its preparation. Further, the present invention relates to a diagnostic kit comprising the self-replicating agent.
  • the technical problem underlying the present invention is to provide a new system for the treatment of diseases caused by pathogenic organisms and for the diagnosis of said diseases and the detection of said pathogenic organisms.
  • a pharmaceutical composition comprising a self-replicating agent directed to a heterologeneous pathogenic organism in a host, and optionally a pharmaceutically acceptable carrier and/or diluent, wherein the self-replicating agent is capable of growth-inhibiting and/or destroying the heterologeneous pathogenic organism without substantial toxicity to the host.
  • a diagnostic kit comprising a self-replicating agent directed to a heterologenous pathogenic organism, wherein the self-replicating agent contains at least one detectable marker gene.
  • the aim of the invention is the infection of the respective pathogenic organism by the self-replicating agent, eventually leading to the destruction or inhibition of the pathogenic organism.
  • This can be achieved by e.g. virulent as well as temperate viruses.
  • Lytic strains of viruses would be of advantage with respect to a spread through the pathogenic population which would enable the use of low titer pharmaceutical compositions which would potentate themself in case of infectability of the pathogenic cells.
  • the initial infection of the pathogenic host organism might be done by use of naked DNA, RNA (e.g. virions), especially encapsulated nucleic acids such as viruses (e.g. eucaryotic viruses and bacteriophages), or specific systems carrying said self replicating agent.
  • Such specific systems may be microsomes and liposomes or invasive bacteria which are already infected with said self replicating agent.
  • Such preinfected invasive bacteria can be used for combatting infections caused by invasive pathogens such as Listeria.
  • a further aim of the invention is the infection of a pathogenic organism by the self-replicating agent, whereby the pathogenic organism can be detected via the marker gene contained in the self-replicating agent upon infection.
  • the term "marker gene” means any nucleotide sequence which is introduced into the genetic material of the self-replicating agent using recombinant DNA techniques, and which can be detected upon infection of the pathogenic organism using known techniques such as PCR, enzymatic methods such as measuring the luminescence, fluorescence and/or immunologic methods. Examples of marker genes are the gene encoding luciferase, chloramphenicolacetyltransferase (CAT) and green fluorescent protein (GFP) .
  • CAT chloramphenicolacetyltransferase
  • GFP green fluorescent protein
  • self-replicating . agent includes, agents, preferably of viral origin such as eukaryotic viruses or bacteriophages, directed specifically to the heterologeneous pathogenic organism.
  • the self-replicating agent may be of natural origin such as naturally occurring eukaryotic viruses or bacteriophages, or may contain at least one nucleotide sequence obtained by recombinant DNA technique, such as a marker gene.
  • self-replicating infectious agents are naturally occurring viruses, viroids or bacteriophages such as Listeria phages A51 1 , B054, or Klebsiella phages K1 1 and Klebsiella pneumoniae bacteriophage or Staphylococcus phage group II as well as viruses infecting eukaryotic cells such as yeast L-A virus, ScVLI , ScVLa, K1 and K2 killervirus, or genetically modified versions thereof.
  • the self-replication of the self-replicating agent is supported by the heterologeneous pathogenic organism.
  • Chlamydia phages such as Chp 1 (Storey et al., Gen. Virol. 70, 1 989, 1 321 -1 327; Bacon et al., Vet. Rec. 1 1 9, 1 986, 61 8-620), Bacillus phages such as phi 20 from the Strain Sterne 34 F7 (Inal and Karunakaran, Curr. Microbiol. 32, 1 996, 1 71 -1 75), CP 54 (Mol. Mikro- biol., Virosol. 1 37, 1 989, 1 4-1 9) and Tg l3 ant (Mol. Gen. Mikrobiol.
  • Trichonomas-RNA virus (Wang and Wang, PNAS 83, 1 986, 7956-7960), Gardiavirus (GLV) (Wang et al., PNAS 90, 1 993, 8595-8599), Leishmania-dsRNA virus L V ⁇ and LRV 2 ., (Widmer and Dooley, Nucleic Acids Res. 23, 1 995, 2300-2304), and Cryptosporidium- dsRNA virus (Khramtsov et al., Mol. Microbiol. 26, 1 997, 289-300).
  • heterologeneous pathogenic organism means any organism, i.e. an eukaryotic or prokaryotic organism, which is capable of infecting a host, and thereby causing a disorder in the host during the course of infection.
  • Such heterologeneous pathogenic organisms include Listeriae, Klebsiellae, Streptococci, Staphylococci, Pneumococci, Moraxellae, Legionellae, Vibrio, Edwardsiellae, Yersiniae, Escherichiae, Haemophilus influenza, Proteus, Heliobacter, Salmonael- la, Chlamydia, Aeromonas salmonicida, Renibacterium salmoninarum, Candida albicans, Leishmania, Trichomonas vaginalis, Giardia lamblia, Cryptosporidium parvum, Plasmodium falciparum, Entamoeba histolytica, Pneumocystis carinii, Tryanosama rhodesiense/gambiense, Trypanosoma cruzi, and bacteriological weapons such as Bacillus anthracis.
  • bacteria such as Listeria monocytogenesor, Klebsiella (K.) ozaenae, K. rhinoscleromatis scleromatis and K. pneumoniae, Staphylococcus aureus, Yersinia ruckeri, Renibacterium salmoni- naram, Vibrio anguillarum, Vibrio cholerae, Vibrio salmonicida, Vibrio viscosus, Edwardsiella ictalari, or fungi such as the yeast Candida albicans, or protozoa such as Leishmania.
  • bacteria such as Listeria monocytogenesor, Klebsiella (K.) ozaenae, K. rhinoscleromatis scleromatis and K. pneumoniae, Staphylococcus aureus, Yersinia ruckeri, Renibacterium salmoni- naram, Vibrio anguillarum, Vibrio cholerae, Vibrio salmonicida,
  • heterologenous pathogenic organisms are Chlamydia such as Chlamydia pneumoniae, Chlamydia trachomatis and Chlamydia psittaci, Moraxella catarrhalis, Salmonella enteritides.
  • host includes vertebrates such as birds, fishes and mammals, preferably humans.
  • the carrier and/or diluent may be in solid or liquid form, and do not exhibit any specific restriction, but should be stabilizing and/or protecting the self-replicating agent, and should have substantially no toxicity for the host.
  • the pharmaceutical composition according to the present invention may be used for the treatment of e.g. bacterial, fungal or protozoal infections of the lung such as pneumonia, infections of skin such as eczema, acne, furunkel-boiis, nasal or throat infections, eye infections, infections of internal organs, ear infections or wound infections, in e.g. vertebrates such as mammals preferably in man.
  • the invention may be used for the treatment of circulating microorganisms in the circulatory systems such as the blood stream or lymphatic circulation, by use of e.g. infusions.
  • the composition according to the present invention can be used for disinfection of e.g.
  • the pharmaceutical composition according to the present invention can be applied to a patient without any specific restricton regarding the amount of the self-replicating agent due to its substantial non-toxicity for the host.
  • the pharmaceutical composition contains a dosage of 10 3 -10 9 phages/application.
  • the formulation of the pharmaceutical composition according to the present invention does not exhibit any specific restriction, and may be prepared e.g. in the form of tablets, suppositories, ointments, solutions, or retarded release- formulations.
  • the pharmaceutical composition according to the present invention can be applied e.g. by way of inhalation, topically, orally, systemically, dependent on the formulation, to a patient suffering from an infection disease caused by a heterologeneous pathogenic microorganism.
  • the formulation of the pharmaceutical composition can be achieved mixing the self-replicating agents in liquid or solid form with suitable carriers.
  • the final mixture can be applied in form of a topically cream, inhalation of a powder or mist, application of suppositories, ointments, infusion solutions, ear drops or eye drops or nose drops or sprays, or using a tape containing said mixture for topical applications.
  • a preferred embodiment of the present invention is a formulation as a phage- lyophilisate to be used in a powder inhalator such as the inhalator disclosed in US-patent 5,673,685.
  • phage-lyophilisates may be used for the treatment of diseases caused by Klebsiella, Pneumococcus, Staphylococcus, Legionella, Haemophilus influenza, and Moraxella catarrhalis.
  • the pharmaceutical composition of the present invention is formulated for topical applications using a substrate such as a bandage (e.g. Tegasorb, 3M) or a tape.
  • Such bandages or tapes may be used for the treatment of diseases caused by Klebsiella, Staphylococcus, Streptococcus and Listeria.
  • the pharmaceutical composition of the present invention is formulated for oral application using e.g. gelatine capsules in gastric juice- resistant or non-resistant form.
  • gelatine capsules may be used for the treatment of diseases caused by Chlamydia, Staphylococcus, Streptococcus, urinary tract infectious agents such as E. coli, Staphylococcus saprophyticus, Proteus mirabiles, Klebsiella and Heliobacter pylori.
  • the self-replicating agent preferably the recombinant phage contained in the diagnostic kit according to the present invention can be used for detecting a pathogenic organism in samples derived from living organisms such as a smear, tissue, blood, urine, stool or sputum from a patient, or in samples derived from e.g. soil, air, water or other areas such as fish ponds for fish farming and/or poultry coops for e.g.
  • the pathogenic organism contained in the sample will be infected with the recombinant phage having a suitable marker gene such as the gene encoding luciferase, chloramphenicolacetyltransferase (CAT) and green flourescent protein (GFP) upon infection the marker gene will be expressed and can be detected with known methods such as measuring the luminescence generated by the expressed luciferase.
  • a suitable marker gene such as the gene encoding luciferase, chloramphenicolacetyltransferase (CAT) and green flourescent protein (GFP)
  • pathogenic organisms to be detected are as listed above.
  • Preferred examples of pathogenic organisms are Chlamydia such as Chlamydia pneumoniae, Chlamydia trachomatis and Chlamydia psittaci, Pneumococci, Haemophilus influenza, Staphylococci such as St. aureus, Moraxellae such as M. catarrhalis, Legionellae, Streptococci, Salmonellae such as Salmonella enteritides, Aeromo- nas salmonicida, and bacteriological weapons such as Bacillus anthracis.
  • the self-replicating agent can be admixed with any suitable carrier and/or diluent in solid or liquid form, but preferably should stabilize and/or protect the self-replicating agent.
  • a further subject of the present invention is a process for the preparation of the above mentioned pharmaceutical composition, comprising the steps of:

Abstract

The present invention relates to a pharmaceutical composition comprising a self-replicating agent directed to a heterologeneous pathogenic organism in a host, and to a process for its preparation. Further, the present invention relates to a diagnostic kit comprising the self-replicating agent.

Description

PHARMACEUTICAL COMPOSITION AND DIAGNOSTIC KIT DIRECTED TO A HETEROLOGENEOUS PATHOGENIC ORGANISM IN A HOST
The present invention relates to a pharmaceutical composition comprising a self- replicating agent directed to a heterologeneous pathogenic organism in a host, and to a process for its preparation. Further, the present invention relates to a diagnostic kit comprising the self-replicating agent.
In the recent years, multi-drug resistance is common among many pathogenic microorganisms. This fact causes severe problems on the treatment of patients infected by such multiple-drug resistant pathogenic microorganisms. However, the development of new effective antibiotics is very time-consuming, and last of all, a drug-resistance of such multiple-drug resistant pathogenic microorganisms against a new effective antibiotic should be expected with high likelihood. Moreover, the scientists agree on the fact that, on the long run, the competition between the development of new effective antibiotics and the generation of resistance of pathogenic microorganisms against said new effective antibiotics will be in favour of the pathogenic microorganisms.
Thus, the technical problem underlying the present invention is to provide a new system for the treatment of diseases caused by pathogenic organisms and for the diagnosis of said diseases and the detection of said pathogenic organisms.
The above technical problem is achieved by providing a pharmaceutical composition comprising a self-replicating agent directed to a heterologeneous pathogenic organism in a host, and optionally a pharmaceutically acceptable carrier and/or diluent, wherein the self-replicating agent is capable of growth-inhibiting and/or destroying the heterologeneous pathogenic organism without substantial toxicity to the host.
Further, there is provided a diagnostic kit comprising a self-replicating agent directed to a heterologenous pathogenic organism, wherein the self-replicating agent contains at least one detectable marker gene.
The aim of the invention is the infection of the respective pathogenic organism by the self-replicating agent, eventually leading to the destruction or inhibition of the pathogenic organism. This can be achieved by e.g. virulent as well as temperate viruses. Lytic strains of viruses would be of advantage with respect to a spread through the pathogenic population which would enable the use of low titer pharmaceutical compositions which would potentate themself in case of infectability of the pathogenic cells. The initial infection of the pathogenic host organism might be done by use of naked DNA, RNA (e.g. virions), especially encapsulated nucleic acids such as viruses (e.g. eucaryotic viruses and bacteriophages), or specific systems carrying said self replicating agent. Such specific systems may be microsomes and liposomes or invasive bacteria which are already infected with said self replicating agent. Such preinfected invasive bacteria can be used for combatting infections caused by invasive pathogens such as Listeria.
A further aim of the invention is the infection of a pathogenic organism by the self-replicating agent, whereby the pathogenic organism can be detected via the marker gene contained in the self-replicating agent upon infection. The term "marker gene" means any nucleotide sequence which is introduced into the genetic material of the self-replicating agent using recombinant DNA techniques, and which can be detected upon infection of the pathogenic organism using known techniques such as PCR, enzymatic methods such as measuring the luminescence, fluorescence and/or immunologic methods. Examples of marker genes are the gene encoding luciferase, chloramphenicolacetyltransferase (CAT) and green fluorescent protein (GFP) .
The term "self-replicating. agent" includes, agents, preferably of viral origin such as eukaryotic viruses or bacteriophages, directed specifically to the heterologeneous pathogenic organism. The self-replicating agent may be of natural origin such as naturally occurring eukaryotic viruses or bacteriophages, or may contain at least one nucleotide sequence obtained by recombinant DNA technique, such as a marker gene. Examples of such self-replicating infectious agents are naturally occurring viruses, viroids or bacteriophages such as Listeria phages A51 1 , B054, or Klebsiella phages K1 1 and Klebsiella pneumoniae bacteriophage or Staphylococcus phage group II as well as viruses infecting eukaryotic cells such as yeast L-A virus, ScVLI , ScVLa, K1 and K2 killervirus, or genetically modified versions thereof. In a preferred embodiment, the self-replication of the self-replicating agent is supported by the heterologeneous pathogenic organism.
Further examples of the self-replicating agent are Chlamydia phages such as Chp 1 (Storey et al., Gen. Virol. 70, 1 989, 1 321 -1 327; Bacon et al., Vet. Rec. 1 1 9, 1 986, 61 8-620), Bacillus phages such as phi 20 from the Strain Sterne 34 F7 (Inal and Karunakaran, Curr. Microbiol. 32, 1 996, 1 71 -1 75), CP54 (Mol. Mikro- biol., Virosol. 1 37, 1 989, 1 4-1 9) and Tgl3ant (Mol. Gen. Mikrobiol. 55, 1 991 , 28-31 ), Salmonella phages type 4 and type 8 (Zentralbl. Bakteriol. 285, 1 997, 379-388) and phages 1 3a, 1 4b, 23, 8 and 2 (Singer et al., Avian, Dis. 36, 1 992, 324-333) and Vibrio cholerae phage 01 39. Further examples of the self- replicating agent against eukaryotic organisms are Trichonomas-RNA virus (Wang and Wang, PNAS 83, 1 986, 7956-7960), Gardiavirus (GLV) (Wang et al., PNAS 90, 1 993, 8595-8599), Leishmania-dsRNA virus L V^ and LRV2., (Widmer and Dooley, Nucleic Acids Res. 23, 1 995, 2300-2304), and Cryptosporidium- dsRNA virus (Khramtsov et al., Mol. Microbiol. 26, 1 997, 289-300).
The term "heterologeneous pathogenic organism" means any organism, i.e. an eukaryotic or prokaryotic organism, which is capable of infecting a host, and thereby causing a disorder in the host during the course of infection. Such heterologeneous pathogenic organisms include Listeriae, Klebsiellae, Streptococci, Staphylococci, Pneumococci, Moraxellae, Legionellae, Vibrio, Edwardsiellae, Yersiniae, Escherichiae, Haemophilus influenza, Proteus, Heliobacter, Salmonael- la, Chlamydia, Aeromonas salmonicida, Renibacterium salmoninarum, Candida albicans, Leishmania, Trichomonas vaginalis, Giardia lamblia, Cryptosporidium parvum, Plasmodium falciparum, Entamoeba histolytica, Pneumocystis carinii, Tryanosama rhodesiense/gambiense, Trypanosoma cruzi, and bacteriological weapons such as Bacillus anthracis. Examples are bacteria such as Listeria monocytogenesor, Klebsiella (K.) ozaenae, K. rhinoscleromatis scleromatis and K. pneumoniae, Staphylococcus aureus, Yersinia ruckeri, Renibacterium salmoni- naram, Vibrio anguillarum, Vibrio cholerae, Vibrio salmonicida, Vibrio viscosus, Edwardsiella ictalari, or fungi such as the yeast Candida albicans, or protozoa such as Leishmania. Further examples of heterologenous pathogenic organisms are Chlamydia such as Chlamydia pneumoniae, Chlamydia trachomatis and Chlamydia psittaci, Moraxella catarrhalis, Salmonella enteritides.
The term "host" includes vertebrates such as birds, fishes and mammals, preferably humans.
The carrier and/or diluent may be in solid or liquid form, and do not exhibit any specific restriction, but should be stabilizing and/or protecting the self-replicating agent, and should have substantially no toxicity for the host.
The pharmaceutical composition according to the present invention may be used for the treatment of e.g. bacterial, fungal or protozoal infections of the lung such as pneumonia, infections of skin such as eczema, acne, furunkel-boiis, nasal or throat infections, eye infections, infections of internal organs, ear infections or wound infections, in e.g. vertebrates such as mammals preferably in man. Furthermore, the invention may be used for the treatment of circulating microorganisms in the circulatory systems such as the blood stream or lymphatic circulation, by use of e.g. infusions. Additionally, the composition according to the present invention can be used for disinfection of e.g. medicine devices such as surgical instruments, dialysis or urinary catheter or conduits, and infusion cannula or conduits. The pharmaceutical composition according to the present invention can be applied to a patient without any specific restricton regarding the amount of the self-replicating agent due to its substantial non-toxicity for the host. In a preferred embodiment of the present application the pharmaceutical composition contains a dosage of 103-109 phages/application.
The formulation of the pharmaceutical composition according to the present invention does not exhibit any specific restriction, and may be prepared e.g. in the form of tablets, suppositories, ointments, solutions, or retarded release- formulations. The pharmaceutical composition according to the present invention can be applied e.g. by way of inhalation, topically, orally, systemically, dependent on the formulation, to a patient suffering from an infection disease caused by a heterologeneous pathogenic microorganism.
The formulation of the pharmaceutical composition can be achieved mixing the self-replicating agents in liquid or solid form with suitable carriers. The final mixture can be applied in form of a topically cream, inhalation of a powder or mist, application of suppositories, ointments, infusion solutions, ear drops or eye drops or nose drops or sprays, or using a tape containing said mixture for topical applications.
A preferred embodiment of the present invention is a formulation as a phage- lyophilisate to be used in a powder inhalator such as the inhalator disclosed in US-patent 5,673,685. Such phage-lyophilisates may be used for the treatment of diseases caused by Klebsiella, Pneumococcus, Staphylococcus, Legionella, Haemophilus influenza, and Moraxella catarrhalis. In a further preferred embodiment the pharmaceutical composition of the present invention is formulated for topical applications using a substrate such as a bandage (e.g. Tegasorb, 3M) or a tape. Such bandages or tapes may be used for the treatment of diseases caused by Klebsiella, Staphylococcus, Streptococcus and Listeria. In yet another preferred embodiment the pharmaceutical composition of the present invention is formulated for oral application using e.g. gelatine capsules in gastric juice- resistant or non-resistant form. Such gelatine capsules may be used for the treatment of diseases caused by Chlamydia, Staphylococcus, Streptococcus, urinary tract infectious agents such as E. coli, Staphylococcus saprophyticus, Proteus mirabiles, Klebsiella and Heliobacter pylori. The self-replicating agent, preferably the recombinant phage contained in the diagnostic kit according to the present invention can be used for detecting a pathogenic organism in samples derived from living organisms such as a smear, tissue, blood, urine, stool or sputum from a patient, or in samples derived from e.g. soil, air, water or other areas such as fish ponds for fish farming and/or poultry coops for e.g. chicken farming, in a preferred embodiment of the present invention the pathogenic organism contained in the sample will be infected with the recombinant phage having a suitable marker gene such as the gene encoding luciferase, chloramphenicolacetyltransferase (CAT) and green flourescent protein (GFP) upon infection the marker gene will be expressed and can be detected with known methods such as measuring the luminescence generated by the expressed luciferase.
Examples of pathogenic organisms to be detected are as listed above. Preferred examples of pathogenic organisms are Chlamydia such as Chlamydia pneumoniae, Chlamydia trachomatis and Chlamydia psittaci, Pneumococci, Haemophilus influenza, Staphylococci such as St. aureus, Moraxellae such as M. catarrhalis, Legionellae, Streptococci, Salmonellae such as Salmonella enteritides, Aeromo- nas salmonicida, and bacteriological weapons such as Bacillus anthracis.
For diagnostic use the self-replicating agent can be admixed with any suitable carrier and/or diluent in solid or liquid form, but preferably should stabilize and/or protect the self-replicating agent.
A further subject of the present invention is a process for the preparation of the above mentioned pharmaceutical composition, comprising the steps of:
(a) sampling the heterologeneous pathogenic organism from a specimen of the host,
(b) inoculating the heterologeneous pathogenic organism with one or more types of self-replicating agents,
(c) selecting and/or adapting the desired self-replicating agent having a high growth-inhibiting and/or destroying effect, and
(d) formulating the pharmaceutical composition.

Claims

Claims
1 . A pharmaceutical composition comprising a self-replicating agent directed to a heterologeneous pathogenic organism in a host, and optionally a pharmaceutically acceptable carrier and/or diluent, wherein the self-replicating agent is capable of growth-inhibiting and/or destroying the heterologeneous pathogenic organism without substantial toxicity to the host.
2. The pharmaceutical composition according to claim 1 , wherein the host is a vertebrate.
3. The pharmaceutical composition according to claim 2, wherein the vertebrate is a mammal.
4. The pharmaceutical composition according to claim 3, wherein the mammal is a human.
5. A diagnostic kit comprising a self-replicating agent for the detection of a pathogenic organism.
6. The pharmaceutical composition or the kit according to anyone of claims 1 to 5, wherein the heterologeneous pathogenic organism is an eukaryotic or prokaryotic organism.
7. The pharmaceutical composition according to claim 6, wherein the pathogenic organism is selected from Listeriae, Klebsiellae, Streptococci, Sta- phylococci, Pneumococci, Moraxellae, Legionellae, Vibrio, Edwardsiellae, Yersiniae, Escherichiae, Haemophilus influenza, Proteus, Heliobacter, Salmonaella, Chlamydia, Aeromonas salmonicida, Renibacterium salmoni- narum, Candida albicans, Leishmania, Trichomonas vaginalis, Giardia lamblia, Cryptosporidium parvum, Plasmodium falciparum, Entamoeba histolytica, Pneumocystis carinii, Tryanosama rhodesiense/gambiense, Trypanosoma cruzi, and bacteriological weapons such as Bacillus an- thracis.
8. The pharmaceutical composition or the kit according to anyone of claims 1 to 7, wherein the self-replication of the self-replicating agent is supported by the heterologeneous pathogenic organism.
9. The pharmaceutical composition or the kit according to anyone of claims 1 to 8, wherein the agent is of viral origin.
1 0. The pharmaceutical composition or the kit according to claim 9, wherein the agent is a bacteriophage.
1 1 . The pharmaceutical composition or the kit according to anyone of claims 1 to 10, wherein the nucleic acid of the self-replicating agent contains at least one nucleotide sequence obtained by recombinant DNA technique.
1 2. The kit according to claim 1 1 , wherein the nucleotide sequence contains a marker gene.
1 3. The pharmaceutical composition according to anyone of claims 1 to 1 1 for the treatment of bacterial, fungal or protozoal infections of the lung, infections of the skin, infections of internal organs, nasal or throut infections, eye infections, ear infections, wound infections or infections of a circulatory system.
1 4. The kit according to any of claims 5 to 1 2 for the detection of a pathogenic organism selected from Listeriae, Klebsiellae, Streptococci, Staphylo- cocci, Pneumococci, Moraxellae, Legionellae, Vibrio, Edwardsiellae, Yersiniae, Escherichiae, Haemophilus influenza, Proteus, Heliobacter, Salmonella, Chlamydia, Aeromonas salmonicida, Renibacterium salmonina- rum, Candida albicans, Leishmania, Trichomonas vaginalis, Giardia lamblia, Cryptosporidium parvum, Plasmodium falciparum, Entamoeba histoly- tica, Pneumocystis carinii, Tryanosama rhodesiense/gambiense, Trypan- osoma cruzi, and bacteriological weapons such as Bacillus anthracis.
5. A process for the preparation of a pharmaceutical composition or the kit according to anyone of claims 1 to 14, comprising the steps of:
(a) sampling the heterologeneous pathogenic organism from a specimen of the host,
(b) inoculating the heterologeneous pathogenic organism with one or more types of self-replicating agents,
(c) selecting and/or adapting the desired self-replicating agent having a high growth-inhibiting and/or destroying effect, and
(d) formulating the pharmaceutical composition or the kit.
PCT/EP1998/002871 1997-05-15 1998-05-15 Pharmaceutical composition and diagnostic kit directed to a heterologeneous pathogenic organism in a host WO1998051318A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP98930692A EP0983077A1 (en) 1997-05-15 1998-05-15 Pharmaceutical composition and diagnostic kit directed to a heterologeneous pathogenic organism in a host
CA002289610A CA2289610A1 (en) 1997-05-15 1998-05-15 Pharmaceutical composition and diagnostic kit directed to a heterologeneous pathogenic organism in a host
AU81043/98A AU8104398A (en) 1997-05-15 1998-05-15 Pharmaceutical composition and diagnostic kit directed to a heterologeneous pathogenic organism in a host

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97107945 1997-05-15
EP97107945.4 1997-05-15
EP97114873 1997-08-27
EP97114873.9 1997-08-27

Publications (1)

Publication Number Publication Date
WO1998051318A1 true WO1998051318A1 (en) 1998-11-19

Family

ID=26145448

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/002871 WO1998051318A1 (en) 1997-05-15 1998-05-15 Pharmaceutical composition and diagnostic kit directed to a heterologeneous pathogenic organism in a host

Country Status (4)

Country Link
EP (1) EP0983077A1 (en)
AU (1) AU8104398A (en)
CA (1) CA2289610A1 (en)
WO (1) WO1998051318A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076483A2 (en) * 2001-03-28 2002-10-03 Danelia Nodar A Bacteriophage preparation
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957686A (en) * 1990-02-06 1990-09-18 Norris Alan H Use of bacteriophages to inhibit dental caries
EP0403292A2 (en) * 1989-06-14 1990-12-19 Microbial Developments Limited Ruminant feedstuff additives
EP0414304A2 (en) * 1989-08-21 1991-02-27 Unilever N.V. Aqueous antibacterial compositions comprising surfactant and bacteriophage
SU1685998A1 (en) * 1989-10-11 1991-10-23 Научно-Производственное Объединение "Бактериофаг" Тбилисского Научно-Исследовательского Института Вакцин И Сывороток Strain of bacteriophage enterobacter aerogenes for diagnostication, prophylaxis and treatment infection, induced by enterobacter aerogenes
WO1995027043A1 (en) * 1994-04-05 1995-10-12 Exponential Biotherapies, Inc. Antibacterial therapy with genotypically modified bacteriophage

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0403292A2 (en) * 1989-06-14 1990-12-19 Microbial Developments Limited Ruminant feedstuff additives
EP0414304A2 (en) * 1989-08-21 1991-02-27 Unilever N.V. Aqueous antibacterial compositions comprising surfactant and bacteriophage
SU1685998A1 (en) * 1989-10-11 1991-10-23 Научно-Производственное Объединение "Бактериофаг" Тбилисского Научно-Исследовательского Института Вакцин И Сывороток Strain of bacteriophage enterobacter aerogenes for diagnostication, prophylaxis and treatment infection, induced by enterobacter aerogenes
US4957686A (en) * 1990-02-06 1990-09-18 Norris Alan H Use of bacteriophages to inhibit dental caries
WO1995027043A1 (en) * 1994-04-05 1995-10-12 Exponential Biotherapies, Inc. Antibacterial therapy with genotypically modified bacteriophage

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 9239, Derwent World Patents Index; Class B04, AN 92-321600, XP002036010 *
LOESSNER M J ET AL: "Construction of luciferase reporter bacteriophage A511::luxAB for rapid and sensitive detection of viable Listeria cells.", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, (1996 APR) 62 (4) 1133-40, XP002079442 *
MERRIL C R ET AL: "Long-circulating bacteriophage as antibacterial agents.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 93 (8). 1996. 3188-3192, XP002044135 *
SMITH H W ET AL: "SUCCESSFUL TREATMENT OF EXPERIMENTAL ESCHERICHIA COLI INFECTIONS IN MICE USING PHAGE: ITS GENERAL SUPERIORITY OVER ANTIBIOTICS", JOURNAL OF GENERAL MICROBIOLOGY, vol. 128, no. PART 02, February 1982 (1982-02-01), pages 307 - 318, XP002036009 *
SMITH H W ET AL: "THE CONTROL OF EXPERIMENTAL ESCHERICHIA COLI DIARRHOEA IN CALVES BY MEANS OF BACTERIOPHAGES", JOURNAL OF GENERAL MICROBIOLOGY, vol. 133, no. PART 05, May 1987 (1987-05-01), pages 1111 - 1126, XP002036008 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
WO2002076483A2 (en) * 2001-03-28 2002-10-03 Danelia Nodar A Bacteriophage preparation
WO2002076483A3 (en) * 2001-03-28 2003-05-01 Nodar A Danelia Bacteriophage preparation

Also Published As

Publication number Publication date
AU8104398A (en) 1998-12-08
CA2289610A1 (en) 1998-11-19
EP0983077A1 (en) 2000-03-08

Similar Documents

Publication Publication Date Title
CN108359644B (en) A kind of wide range salmonella bacteriophage and its application
EP2780447B1 (en) Novel isolated bacteriophage having e. coli-specific bactericidal activity and antibacterial composition comprising the same
US8288146B2 (en) Salmonella bacteriophage and antibacterial composition comprising the same
WO2022048061A1 (en) Salmonella phage having high temperature tolerance and wide lysis spectrum and composition thereof
ES2612916T3 (en) New active bacteriophage against Salmonella and antibacterial composition comprising the same
ES2562640T3 (en) New bacteriophage and antibacterial composition comprising the same
US20240082328A1 (en) Bacteriophage Composition And Method of Preventing Bacterial Infections in Livestock
US9745555B2 (en) Bacteriophage and antibacterial composition comprising the same
US9657277B2 (en) Bacteriophage and antibacterial composition comprising the same
US9862935B2 (en) Bacteriophage and antibacterial composition comprising the same
US20180282703A1 (en) Novel bacteriophage and antibacterial composition comprising the same
CN113416712B (en) Wide lysis spectrum salmonella bacteriophage and application thereof
US20110052542A1 (en) Novel bacteriophage and antibacterial composition comprising the same
CN113337480B (en) Broad-spectrum coliphage and application thereof
CN113583971B (en) Salmonella bacteriophage capable of simultaneously cracking escherichia coli and application thereof
CN111363724B (en) Novel bacteriophage, bacteriophage mixed preparation and application of novel bacteriophage and bacteriophage mixed preparation in medicine for preventing and treating hemorrhagic pneumonia of mink
WO2011028061A2 (en) Novel bacteriophage and antibacterial composition comprising the same
EP0983077A1 (en) Pharmaceutical composition and diagnostic kit directed to a heterologeneous pathogenic organism in a host
US20110052543A1 (en) Novel bacteriophage and antibacterial composition comprising the same
CN113444696B (en) Aeromonas hydrophila phage and application thereof
CN113337474B (en) Vibrio parahaemolyticus lytic phage vB _ VpP _ DE17 and application thereof
RU2758862C1 (en) Method for destruction of m.p. pokrovskaya's bacteriophage nucleocapsid
CN113528470B (en) T4SS targeted phage vB _ EcoM _ X4 and application thereof
CN113430176B (en) Stable and efficient salmonella furnacalis bacteriophage RDP-SA-21004 and application thereof
CN117264910B (en) Phage resistant to Gao Wenan spectrum salmonella and clinical application thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2289610

Country of ref document: CA

Ref country code: CA

Ref document number: 2289610

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998930692

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998548815

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1998930692

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09423935

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1998930692

Country of ref document: EP